PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches -
- PGN-EDO51 was generally well-tolerated -
- PepGen plans to initiate a Phase 2a multiple ascending dose (MAD) clinical trial in Duchenne muscular dystrophy (DMD) patients in 1H 2023 -
- Data supports the potential of PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform in neuromuscular diseases -
- Company to host conference call today at 8:00 a.m. ET to discuss these results -
PepGen will host a corresponding conference call and a live webcast at 8:00 a.m. ET on September 28, 2022, to discuss the topline results from its Phase 1 HNV trial of PGN-EDO51. Individuals interested in listening to the conference call by webcast may do so by registering via the webcast link in the investor relations section of the company's website at: www.pepgen.com.
https://finance.yahoo.com/news/pepgen-reports-positive-data-phase-100000105.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.